Anthropic Publishes Early Progress of Claude in Drug Discovery
On October 27, 2026, Anthropic released a life sciences progress update, disclosing early results from collaborations with six institutions—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—as well as its first in-house drug program. Six scientists at Generate used Claude Code to build an agent system and selected candidates from 186 CAR T cell therapy signaling domain redesigns; one design was about 70% shorter than the standard version, and in laboratory tests the number of cell surface receptors was about 10 times the original. Divergence Labs said Claude generated about 35,000 antibody designs under about 2,750 hours of H100 compute, and 20 of the 91 tested disruptor designs measurably stripped already-bound IgE. Enveda used Claude to review 1,061 pages of production batch records, reducing review time from 25.9 hours to 2.8 hours, and said drafting Module 2 of an investigational new drug application was shortened from about three months to four hours. Anthropic emphasized that these results are still early, mostly preclinical, and safety and efficacy have not yet been validated in patients.
On October 27, 2026, Anthropic released a life sciences progress update, disclosing early results from collaborations with six institutions—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—as well as its first in-house drug program. Six scientists at Generate used Claude Code to build an agent system and selected candidates from 186 CAR T cell therapy signaling domain redesigns; one design was about 70% shorter than the standard versi
Matched fieldsBody
